Human Oestradiol ELISA Kit

This study aimed to investigate the effect of three different doses of estradiol-17 beta on ovulation and subsequent luteal development and function in llamas. Twenty-three llamas were examined daily by transrectal ultrasonography until the detection of an ovulatory follicle (>= 8 mm). Thereafter, animals were divided into five groups: Control (n = 3; treated with 1.6 ml of saline solution), GnRH group (n = 6, treated with an intravenous injection of 8.4 mu g Buserelin), and estradiol groups that received 0.6 mg (E1, n = 4), 1 mg (E2, n = 4), or 1.6 mg (E3, n = 6) of estradiol-17 beta intravenously. Detection of ovulation was based on ultrasonographic visualization of disappearance of the largest follicle and subsequent presence of a newly formed corpus luteum (CL) and progesterone concentration exceeding 1 ng ml(-1). Daily blood samples were collected to determine plasma progesterone concentration. Ovulation rate was 0% for control and E1 groups, 25% for E2 group, and 100% for GnRH and E3 groups. Differences in the mean CL diameter between GnRH and E3 groups were not statistically significant. Plasma progesterone concentration was similar between groups during the different days in ovulated animals. However, the day that the plasma progesterone concentration was above 1 ng ml(-1) and the day that the highest plasma progesterone concentration was achieved differed among E3 and GnRH groups, occurring later in females treated with estradiol. In conclusion, an injection of estradiol-17 beta is capable of inducing ovulation in llamas and the response depends on the dose used. Most of the animals required the highest tested dose (1.6 mg) to induce the ovulatory process. Although the CL diameter in females induced to ovulate with estradiol was similar to that in llamas induced to ovulate with a GnRH analog, the rise in plasma progesterone concentration above 1 ng ml(-1) and the peak progesterone concentration were attained 1 day later in the estradiol treated females.

Background: To study the association of manganese intake from diet with depressive symptoms in midlife women. Methods: Data for this cross-sectional study were retrieved from baseline assessment of the Study of Women's Health Across the Nation (SWAN). Linear regression, logistic regression and restricted cubic spline models were performed to examine the association of manganese intake with depressive symptoms. Results: A total of 2993 midlife women aged 42-52 years were included in the present study. In premenopausal women, manganese intake was inversely associated with CES-D score and after adjustment for total caloric intake, age, race/ethnicity, education, income, financial strain, physical activity, BMI, vasomotor symptoms, chronic stress and use of antidepressant, estradiol, testosterone and sex hormone binding globulin using linear regression. The fully adjusted regression coefficient 95% confidence intervals (CIs) were -0.533 (-0.993, -0.074). Similarly, manganese intake was inversely associated with depressive symptoms (CES-D scores >= 16) using logistic regression adjusted same confounders. The fully adjusted odds ratios (ORs) with 95% CI of depressive symptoms were 0.512 (0.287-0.913) in quartile 4 compared with quartile 1 for manganese intake. However, in early perimenopausal women, no statistically significant difference was observed between manganese intake and depressive symptoms after adjustment for same confounders that adjusted in premenopausal women. Limitations: This was a cross-sectional study, limiting causal inferences. Assessment of CES-D was based on a self-report scale. Conclusion: Manganese intake may be inversely associated with depression symptoms in premenopausal women, but not in early perimenopausal women.